Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Galderma Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: $22.9B

Website: http://www.galderma.com/

Clinical Trials

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

Phase 2

Completed

Conditions: Platysmal Bands

Interventions: Biological: AbobotulinumtoxinA dose 1
Biological: AbobotulinumtoxinA dose 3
Biological: AbobotulinumtoxinA dose 2
Other: Placebo

First Posted Date: 2019-09-06

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 80

Registration Number: NCT04080882

Locations: 🇺🇸
Galderma Research Site, New York, New York, United States

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Moderate-to-Severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Nemolizumab

First Posted Date: 2019-06-18

Last Posted Date: 2024-08-14

Lead Sponsor: Galderma R&D

Target Recruit Count: 787

Registration Number: NCT03989349

Locations: 🇺🇸
Galderma Investigational Site 8749, Birmingham, Alabama, United States
🇺🇸
Galderma Investigational Site 8893, Birmingham, Alabama, United States
🇺🇸
Galderma Investigational Site 8866, Guntersville, Alabama, United States

and more 135 locations

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Phase 3

Active, not recruiting

Conditions: Moderate-to-Severe Atopic Dermatitis

Interventions: Drug: Nemolizumab

First Posted Date: 2019-06-18

Last Posted Date: 2024-10-30

Lead Sponsor: Galderma R&D

Target Recruit Count: 1700

Registration Number: NCT03989206

Locations: 🇺🇸
Galderma Investigational Site 8749, Birmingham, Alabama, United States
🇺🇸
Galderma Investigational Site 8893, Birmingham, Alabama, United States
🇺🇸
Galderma Investigational Site 8866, Guntersville, Alabama, United States

and more 339 locations

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Moderate-to-Severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Nemolizumab

First Posted Date: 2019-06-14

Last Posted Date: 2024-08-14

Lead Sponsor: Galderma R&D

Target Recruit Count: 941

Registration Number: NCT03985943

Locations: 🇺🇸
Galderma Investigational Site 8880, North Little Rock, Arkansas, United States
🇺🇸
Galderma Investigational Site 8578, Cerritos, California, United States
🇺🇸
Galderma Investigational Site 8636, Fountain Valley, California, United States

and more 171 locations

Study to Evaluate Satisfaction After Treatment With Kysse

Not Applicable

Completed

Conditions: Lip Augmentation

Interventions: Device: Hyaluronic acid

First Posted Date: 2019-05-30

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 59

Registration Number: NCT03967444

Locations: 🇨🇦
Galderma Study Site, Toronto, Canada

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Phase 3

Completed

Conditions: Glabellar Frown Lines

Interventions: Other: Placebo
Biological: AbobotulinumtoxinA

First Posted Date: 2019-05-23

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 301

Registration Number: NCT03960957

Locations: 🇺🇸
Galderma Study Site, Spring, Texas, United States

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Nemolizumab

First Posted Date: 2019-04-19

Last Posted Date: 2023-04-21

Lead Sponsor: Galderma R&D

Target Recruit Count: 20

Registration Number: NCT03921411

Locations: 🇺🇸
Galderma Investigational Site, Richmond, Virginia, United States

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Trifarotene

First Posted Date: 2019-04-16

Last Posted Date: 2021-12-15

Lead Sponsor: Galderma R&D

Target Recruit Count: 47

Registration Number: NCT03915860

Locations: 🇺🇸
Galderma Investigational Site, Richardson, Texas, United States

A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) Fillers

Not Applicable

Completed

Conditions: Volume Deficiency of the Midface

Interventions: Device: Restylane Volyme
Device: Restylane Defyne
Device: Restylane Lyft Lidocaine

First Posted Date: 2019-03-11

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 90

Registration Number: NCT03869450

Locations: 🇬🇧
Galderma Research Site, Edinburgh, United Kingdom

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

Not Applicable

Completed

Conditions: Nasolabial Folds

Interventions: Device: Sculptra Aesthetic 8ml
Device: Sculptra Aesthetic 5ml

First Posted Date: 2018-12-19

Last Posted Date: 2022-11-14

Lead Sponsor: Galderma R&D

Target Recruit Count: 80

Registration Number: NCT03780244

Locations: 🇺🇸
Galderma Study Site, Spring, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy